Quick Answer
Bolt Biotherapeutics, Inc. reported Cash and Equivalents of $11.70 million for fiscal year 2025.
Bolt Biotherapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $11.70M | +62.4% |
| 2024 | $7.21M | -33.3% |
| 2023 | $10.81M | +16.9% |
| 2022 | $9.24M | -66.2% |
| 2021 | $27.38M | +394.1% |
| 2020 | $5.54M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $17.75M | +89.5% | +84.9% |
| June 30, 2025 | $9.60M | +54.8% | +14.4% |
| March 31, 2025 | $8.39M | +96.9% | +16.5% |
| December 31, 2024 | $7.21M | -33.3% | -23.1% |
| September 30, 2024 | $9.37M | +2.2% | +51.0% |
| June 30, 2024 | $6.20M | -53.9% | +45.5% |
| March 31, 2024 | $4.26M | -71.3% | -60.6% |
| December 31, 2023 | $10.81M | +16.9% | +18.0% |
- Bolt Biotherapeutics, Inc. showed an increase of +62.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Bolt Biotherapeutics, Inc.’s cash and equivalents has grown by 111.2% (from $5.54 million to $11.70 million).
- The most recent figure is from Bolt Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: